AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (11.6 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Research Article | Open Access

Synergistic Effects of Nanoemulsion and Deferiprone (1, 2 Dimethyl-3-Hydroxypyrid-4-One) on Multi-Drug Resistant Acinetobacter baumannii

Karthikeyan Ramalingam1( )Valerie Lee2
School of Life Sciences, B.S. Abdur Rahman Crescent Institute of Science and Technology, Vandalur, Chennai, Tamil Nadu, 600048 India
Department of Comprehensive Dentistry, University of Texas Health at San Antonio, 7703 Floyd Curl Drive, San Antonio, Texas 78229-3900, USA
Show Author Information

Abstract

Nosocomial infections caused by Acinetobacter baumannii (A. baumannii) are exceedingly difficult to treat, particularly in immune-compromised patients. Nanoemulsions (NEs) are a distinctive category of disinfectants that have wide range of bactericidal, fungicidal and antiviral properties by damaging their outer membranes. The inhibiting potential of iron chelators such as deferiprone (DF) used as remedial agent for different microbial groups. Combining new generation disinfectant NEs and the iron chelator DF is a logical approach to control of A. baumannii planktonic and biofilm infections. Present studies investigated the bactericidal efficacy of NE with DF by testing their minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) against four strains of A. baumannii. We analyzed adherence of the planktonic form both with and without deferiprone to determine possible enhancement effects. The mechanism of nanoemulsion with deferiprone (NE/DF) was quantified by LIVE/DEAD staining biofilm assay and scanning electron microscopy. DF does not affect the stability of the nanoemulsion and the combined forms show high stability. From MBC, NE/DF showed enhanced activity up to 2- to 3.3-fold compared to nanoemulsion and deferiprone alone. Combined nanoemulsion with deferiprone showed higher adherence inhibition compared to the individual forms. From confocal imaging, the level of dead cell intensity was 84.9% to 96.6% in NE/DF treated groups. Bacteria treated with NE, DF and NE/DF confirms morphological variations when compared to pili-bonded integrated control cells. We propose that biofilm destruction starts from pili removal followed by membrane destruction. These results leave a concrete evidence for the employment of nanoemulsion with deferiprone for the treatment of against drug resistant A. baumannii.

References

[1]

K. Ramalingam, B.T. Amaechi, H.R. Rawls, et al., Antimicrobial activity of nanoemulsion on cariogenic planktonic and biofilm organisms. Arch Oral Biol, 2012, 57: 15-22.

[2]

T. Hamouda, M.M. Hayes, and Z. Cao, A novel surfactant nanoemulsion with broad-spectrum sporicidal activity against Bacillus spores. J Infect Dis., 1999, 180: 1939-1949.

[3]
D.C. Wright, Antimicrobial oil-in-water emulsions. US patent 5, 475, 667, 1996.
[4]

V.A. Lee, R. Karthikeyan, H.R. Rawls, et al., Anticariogenic effect of a cetylpyridinum chloride containing nanoemulsion. J Dent, 2010, 38: 742-749.

[5]

T. Hamouda, A. Myc, B. Donovan, et al., A novel surfactant nanoemulsion with a unique nonirritant topical antimicrobial activity against bacteria enveloped viruses and fungi. Microbiol Res, 2001, 156: 1-7.

[6]

B.W. Donovan, J.D. Reuter, Z. Cao, et al., Prevention of murine influenza A virus pneumonitis by surfactant nano-emulsions. Antivir Chem Chemother, 2001, 11: 41-49.

[7]

C.M. Kim, S.H. Shin, Effect of iron-chelator deferiprone on the in vitro growth of staphylococci. J Korean Med Sci, 2009, 24: 289-295.

[8]

S.S. Fernandes, A. Nunes, A.R. Gomes, et al., Identification of a new hexadentate iron chelator capable of restricting the intra macrophagic growth of Mycobacterium avium. Microbes Infect. , 2010, 12: 287-294.

[9]

Z. Debebe, T. Ammosova, D. Breuer, et al., Iron chelators of the di-2-pyridylketone thiosemicarbazone and 2-benzoylpyridine thiosemicarbazone series inhibit HIV-1 transcription: identification of novel cellular targets-iron, cyclin-dependent kinase (CDK) 2, and CDK9. Mol Pharmacol., 2011, 79: 185-196.

[10]

P. Chakrabarty, S. Rudra, M.A. Hossain, et al., Iron chelation therapy and thalassemia - an overview. Mymensingh Med J., 2011, 20: 513-519.

[11]

H. Heli, S. Mirtorabi, K. Karimian, Advances in iron chelation: An update. Expert Opin Ther Pat., 2011, 21: 819-856.

[12]

H.W. Boucher, G.H. Talbot, J.S. Bradley, et al., Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. , 2009, 48: 1-12.

[13]

J.F. Turton, M.E. Kaufmann, M. Warner et al., A prevalent, multiresistant clone of Acinetobacter baumannii in Southeast England. J Hosp Infect. , 2004, 58: 170-179.

[14]

K.J. Towner, Acinetobacter: An old friend, but a new enemy. J Hosp Infect., 2009, 73: 355-363.

[15]

J. Vila, J. Pachon, Therapeutic options for Acinetobacter baumannii infections. Expert Opin Pharmacother. , 2008, 9: 587-599.

[16]

A.P. Zavascki, C.G. Carvalhaes, R.C. Picao et al., Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther., 2010, 8: 71-93.

[17]

T.L. Stuart, M. Mulvey, A.E. Simor, et al., Acinetobacter baumannii in casualties returning from Afghanistan. Can J Infect Control, 2007, 22: 152-154.

[18]

T.R. Neu, J.R. Lawrence, Development and structure of microbial stream biofilms as studied by confocal laser scanning microscopy. FEMS Microb Ecol. , 1997, 24: 11-25.

[19]

J.C. Araujo, F.C. Teran, R.A. Oliveira, et al., Comparison of hexamethyldisilazane and critical point drying treatments for SEM analysis of anaerobic biofilms and granular sludge. J Electron Microsc (Tokyo), 2003, 52: 429-433.

[20]

M.J. Lawrence, G.D. Rees, Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev. , 2000, 45: 89-121.

[21]

P.C. Teixeira, G.M. Leite, R.J. Domingues, et al., Antimicrobial effects of a microemulsion and a nanoemulsion on enteric and other pathogens and biofilms. Int J Food Microbiol. , 2007, 118: 15-19.

[22]

A. Myc, T. Vanhecke, J.L. Landers et al., The fungicidal activity of novel nanoemulsion (X8W60PC) against clinically important yeast and filamentous fungi. Mycopathologia, 2001, 155: 195-201.

[23]

M.G. Thompson, B.W. Corey, Y. Si, et al., Antibacterial activities of iron chelators against common nosocomial pathogens. Antimicrob Agents Chemother. , 2012, 56(10): 5419-5421.

[24]

B. Lesic, J. Foulon, E. Carniel, Comparison of the effects of deferiproneversus deferoxamine on growth and virulence of Yersinia enterocolitica. Antimicrob Agents Chemother. , 2002, 46: 1741-1745.

[25]

C.M. Kim, R.Y. Park, M.H. Choi et al., Ferrophilic characteristics of Vibrio vulnificus and potential usefulness of iron chelatingtherapy. J Infect Dis. , 2007, 195: 90-98.

[26]

A. Tomaras, C. Dorsey, R. Edelmann, et al., Attachment to and biofilm formation on abiotic surfaces by Acinetobacter baumannii: Involvement of a novel chaperone-usher pili assembly system. Microbiology, 2003, 149: 3473-3484.

[27]

G.F.M. Moura Costa, M.C.B. Tognim, C.L. Cardoso, et al., Preliminary evaluation of adherence on abiotic and cellular surfaces of Acinetobacter baumannii strains isolated from catheter tips. Braz J Infect Dis. , 2006, 10: 346-351.

[28]

I.S.I. Al-Adham, E. Khalil, N.D. Al-Hmoud, et al., Microemulsions are membrane-active, antimicrobial, self preserving systems. J Appl Microbiol. , 2000, 89: 32-39.

[29]

A.M. Bodor, L. Jansch, J. Wissing, et al., The luxS mutation causes loosely-bound biofilms in Shewanella oneidensis. BMC Res Notes, 2011, 4: 180.

[30]

K. Flemming, C. Klingenberg, J.P. Cavanagh, et al., High in vitro antimicrobial activity of synthetic antimicrobial peptidomimetics against staphylococcal biofilms. J Antimicrob Chemother. , 2009, 63: 136-145.

[31]

R.T. Ellison 3rd, T.J. Giehl, Killing of Gram-negative bacteria by lactoferrin and lysozyme. J Clin Invest, 1991, 88: 1080-1091.

[32]

J.S. Pinkner, H. Remaut, F. Buelens, et al., Rationally designed small compounds inhibit pilus biogenesis in uropathogenic bacteria. Proc Natl Acad Sci USA, 2006, 103: 17897-17902.

[33]
L.B. Purevdorj-Gage LB.P. Stoodley, Biofilm structure, behavior, and hydrodynamics. Microbial biofilms. ASM Press, 2004: 160-173.
[34]

T. Moretro, S. Langsrud, Listeria monocytogenes: biofilm formation and persistence in food processing environments. Biofilms, 2004, 1: 107-121.

[35]
J.R. Baker Jr, T. Hamouda, A. Shih, et al., Non-toxic antimicrobial compositions and methods of use. US Patent 6, 635, 676, 2003.
[36]

H.L. Ennis HL Bacterial resistance to the synergistic antibiotics of the PA 114, streptogramin, and vernamycin complexes. J Bacteriol, 1967, 93: 1881-1887.

[37]

L. Leive, Release of lipopolysaccharide by EDTA treatment of E. coli. Biochem Biophys Res Commun, 1965, 21: 290-296.

[38]

I. Raad, I. Chatzinikolaou, G. Chaiban, In vitro and ex vivo activities of minocycline and EDTA against microorganisms embedded in biofilm on catheter surfaces. Antimicrob Agents Chemother, 2003, 47: 3580-3585.

[39]

L. Leseleuc, G. Harris, R.K. Lee, et al., In vitro and in vivo biological activity of iron chelators and gallium nitrate against Acinetobacter baumannii. Antimicrob Agents Chemother, 2012, 56(10): 5397-5400.

[40]

A.S. Ibrahim, T. Gebermariam, Y. Fu, et al., The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest, 2007, 117: 2649-2657.

Nano Biomedicine and Engineering
Pages 226-237
Cite this article:
Ramalingam K, Lee V. Synergistic Effects of Nanoemulsion and Deferiprone (1, 2 Dimethyl-3-Hydroxypyrid-4-One) on Multi-Drug Resistant Acinetobacter baumannii. Nano Biomedicine and Engineering, 2019, 11(3): 226-237. https://doi.org/10.5101/nbe.v11i3.p226-237

457

Views

17

Downloads

4

Crossref

3

Scopus

Altmetrics

Received: 26 March 2019
Accepted: 13 July 2019
Published: 23 July 2019
© Karthikeyan Ramalingam, Valerie Lee.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Return